• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Novo Nordisk’s Wegovy approved by MHRA in the UK for cardiovascular prevention

by July 23, 2024
written by July 23, 2024

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk’s weight loss drug, Wegovy, for the prevention of serious cardiovascular events in overweight and obese adults. 

This landmark decision marks the first time a GLP-1 obesity drug is prescribed for such a purpose in the UK, following a similar approval by the U.S. Food and Drug Administration earlier this year.

Following the announcement, shares of Novo Nordisk rose 1.46% by 4:10 p.m. London time. 

The MHRA’s decision represents a significant step forward in addressing the health risks associated with obesity, offering a new therapeutic option that extends beyond mere weight management.

Impact on the obesity treatment landscape

The approval is supported by the results of the “SELECT” trial, a late-stage study published in August 2023. 

The trial demonstrated Wegovy’s effectiveness in reducing major cardiovascular events by 20% compared to a placebo, underscoring its potential to significantly impact public health outcomes.

Initially approved in the UK for obesity treatment and weight management, Wegovy has now expanded its therapeutic scope. 

Previously used alongside diet, physical activity, and behavioral support, the drug’s new approval aims to shift its perception from a “vanity drug” to a vital treatment for preventing heart disease and strokes in individuals with obesity.

Addressing serious health consequences of obesity

Shirley Hopper, MHRA’s deputy director of innovative medicines, emphasized the importance of this approval in combating obesity-related health issues. 

She assured that Wegovy has met the necessary regulatory standards of safety, quality, and effectiveness, paving the way for its use as a preventive measure against cardiovascular events.

The approval of Wegovy for cardiovascular prevention is expected to have broad implications for healthcare providers and patients. 

It offers a new avenue for managing obesity-related health risks, potentially reducing the incidence of heart disease and strokes among overweight and obese individuals.

Expanding therapeutic options

With the new approval, Novo Nordisk aims to reinforce the clinical value of Wegovy and fend off growing competition in the obesity treatment market. 

The company’s strategy focuses on expanding the drug’s therapeutic indications to address both weight management and cardiovascular risk reduction.

The approval aligns with broader public health strategies aimed at reducing the burden of obesity-related diseases. 

By providing a pharmacological option that addresses both weight loss and cardiovascular risk, Wegovy could play a crucial role in comprehensive obesity management programs.

Healthcare professionals anticipate that the expanded use of Wegovy could lead to improved patient outcomes by addressing multiple aspects of obesity-related health risks. 

This multifaceted approach could enhance the overall effectiveness of obesity treatment plans and reduce the long-term burden on healthcare systems.

Future research and clinical practice

The approval of Wegovy for cardiovascular risk prevention opens new avenues for research and clinical practice. 

Future studies may explore additional benefits and potential applications of GLP-1 drugs in various populations, further solidifying their role in modern medicine. 

Novo Nordisk is likely to continue its research and development efforts to explore the full potential of Wegovy and similar drugs, leading to the discovery of new therapeutic uses and further improvements in patient care.

By addressing both weight loss and cardiovascular risk, Wegovy stands to make a significant impact on public health, potentially transforming the management of obesity-related conditions in the UK and beyond.

The post Novo Nordisk’s Wegovy approved by MHRA in the UK for cardiovascular prevention appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Long OTIS: Otis Worldwide Corp Near Breakout, Enter Trade During Consolidation Phase
next post
Lack of charging infrastructure hinders electric vehicle adoption in Europe, new poll reveals

related articles

Asian markets close: Nikkei, Kospi down; Sensex closes...

May 19, 2025

Qualcomm unveils AI chips for data centres with...

May 19, 2025

Best crypto to buy now: Bitcoin Pepe leads...

May 19, 2025

JPMorgan cuts Netflix rating, citing balanced risk-reward post-rally;...

May 19, 2025

Bitcoin ETF open interest dips 5% to $29.47B...

May 19, 2025

US stocks slip in the red on Monday:...

May 19, 2025

Should Klarna IPO remain on watch list after...

May 19, 2025

Why this brokerage downgraded UnitedHealth’s rating to ‘hold’

May 19, 2025

Nvidia opens NVLink Fusion ecosystem, expands Taiwan footprint...

May 19, 2025

Cathie Wood says Trump’s tariffs could unlock tech...

May 19, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • China Stocks Strife Due to Economic Slowdown

    August 12, 2024
  • Cargo thieves are attacking the U.S. supply chain at alarming rates

    May 10, 2025
  • US and Iran clash over uranium enrichment as nuclear talks resume in Rome

    May 23, 2025
  • Wave of court orders blocking Trump’s agenda are a ‘judicial coup d’etat,’ Gingrich says

    April 1, 2025
  • US hits ISIS camps in Syria, killing nearly 3 dozen terrorists

    October 30, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,723)
  • Investing (624)
  • Stock (773)

Latest Posts

  • Biden stages hour-long press conference, takes multiple questions in bid to allay fears over mental decline

    July 12, 2024
  • Crypto market snapshot, Dec 4: Bitcoin at $96K, Tron soars 75%

    December 4, 2024
  • MORNING GLORY: The VP debate is an example of Kamala Harris’s horrible judgment when it comes to picking staff

    October 3, 2024

Recent Posts

  • Millennials reimagine retirement: ‘The end game might not be … sitting on my Adirondack chair’

    February 4, 2025
  • The dollar index remains in a bearish trend this week

    August 21, 2024
  • Mark Milley pardoned: General at center of Afghanistan withdrawal predicted it wouldn’t be a Saigon moment

    January 20, 2025

Editor’s Pick

  • The S&P 500 and Nasdaq retreated to new lows yesterday

    October 2, 2024
  • Oil and natural gas: Oil slides to new low as stocks fall

    August 5, 2024
  • Grenell developing ‘common sense’ plan to turn Kennedy Center financials around

    March 15, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock